You are here: Industry Insights > cystic fibrosis

News List

Vertex presents real-world data highlighting benefit of CF drug Kalydeco pharmatimes
July 06, 2018
Vertex has presented long-term, observational data highlighting the benefit of Kalydeco in patients with cystic fibrosis.
Vertex doubles size of cystic fibrosis drug discovery site fiercebiotech
June 25, 2018
Vertex has more than doubled the size of the San Diego research site that discovered its key cystic fibrosis drugs.
Cystic fibrosis: Company urged to lower cost of life-changing drug firstwordpharma
April 24, 2018
Health ministers in the UK have urged Vertex Pharmaceuticals to drop the price of its cystic fibrosis drug Orkambi for NHS patients, reported BBC News.
Vertex Receives CHMP Positive Opinion for ORKAMBI for Children with Cystic Fibrosis americanpharmaceuticacreview
November 13, 2017
Positive CHMP opinions are recommendations for approval to the European Commission, which has the authority to approve medicines for the European Union.
ANTABIO Awarded Up to USD8.9M from CARB-X to Accelerate the Development of Its New Treatment For Chr b3cnewswire
July 26, 2017
Antabio SAS announced today that it has been awarded up to $8.9 million non-dilutive funding from CARB-X, the world's largest public-private partnership devoted to antibacterial R&D.
FDA Expands Approved Use of Kalydeco to Treat Additional Mutations of Cystic Fibrosis drugs.com
May 18, 2017
The U.S. Food and Drug Administration today expanded the approved use of Kalydeco (ivacaftor) for treating cystic fibrosis.
Cystic Fibrosis Survival Better in Canada Than in U.S. drugs.com
March 14, 2017
People with cystic fibrosis are living longer than ever, but those in Canada live nearly 10 years longer than those in the United States, a new study finds.
Vertex to acquire CTP-656 from Concert Pharmaceuticals for the treatment of cystic fibrosis cphi-online
March 08, 2017
Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating the underlying cause of CF.
HUB and Dutch health insurance companies to validate use of Organoids for Cystic Fibrosis pharmaasia
January 26, 2017
HUB Organoids have demonstrated to be valuable disease models for screening and validation of innovative medicines.
Concert Pharmaceuticals receives FDA orphan drug designation for CTP-656 for the treatment of CF cphi-online
January 24, 2017
Topline results from the Phase II trial are expected by year-end 2017.

Previous page 1 2 3 4 5 6 Next page